Form 4: Rapport Therapeutics CDO Sells Over 10,000 Shares

Rapport Therapeutics' Chief Development Officer, Yeleswaram Krishnaswamy, sold 10,115 shares of common stock for approximately $30 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Chief Development Officer Yeleswaram Krishnaswamy sold 10,115 shares of Rapport Therapeutics, Inc. common stock.
• The transaction occurred on March 25, 2026.
• The shares were sold at a weighted average price of $29.9906, with individual sales ranging from $29.90 to $30.18.
• The sale was executed under a Rule 10b5-1 trading plan adopted on December 10, 2025.
• Following the transaction, Krishnaswamy beneficially owns 286,876 shares directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative signal due to the insider sale, though the pre-arranged 10b5-1 plan suggests it's part of routine financial planning rather than a reaction to adverse company-specific news.

Negatives

• An insider, the Chief Development Officer, sold 10,115 shares of company stock, which can sometimes be interpreted as a lack of confidence, despite being pre-planned.

Future Outlook

No future outlook or guidance is provided in this insider transaction report.

Industry Context

StockSavvy.ai notes that insider sales, even those pre-scheduled under a 10b5-1 plan, are routinely monitored by investors for potential signals regarding management's perception of future company performance or valuation. Such transactions are common for executive compensation and personal financial planning.

Comparison to Industry Standards

• This filing is a standard insider transaction report, common across all publicly traded companies when executives buy or sell shares. No specific industry-comparable companies or projects are detailed within this type of filing.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slight negative signal, potentially impacting investor confidence, though the 10b5-1 plan provides context for the transaction.

Key Dates

Recommendation

The insider sale, while by a key executive, was conducted under a pre-arranged 10b5-1 plan, which often indicates personal financial planning rather than a bearish view on the company's immediate prospects. Without additional information on company performance or other market factors, this single transaction does not warrant a change from a neutral 'hold' stance.

Keywords

Rapport Therapeutics, RAPP, Insider Sale, Form 4, Yeleswaram Krishnaswamy, Chief Development Officer, Stock Transaction, 10b5-1 Plan